Marco Renazco
Psychiatry · Katy, TXNPI 1518038751
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,500 of the $30,729 with a category attached, or 66.7%. AbbVie accounts for 70.6% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2020 at $10,802 and has fallen 85.9% since, to $1,521 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 398 payments — averaging $77.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$22K
- Johnson & Johnson$3K
- Vanda Pharmaceuticals Inc.$681
- Otsuka America Pharmaceutical, Inc.$592
- Takeda Pharmaceuticals U.S.A., Inc.$584
- MDD US Operations, LLC$561
- plus $4K from 27 others
What the payments were for
- Consulting fees$2,0007%
- Speaking & faculty fees$20,50067%
- Travel & lodging$2281%
- Food & beverage$7,82625%
- Education$1751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 101 | $21,686 |
| Johnson & Johnson | 15 | $2,651 |
| Vanda Pharmaceuticals Inc. | 36 | $681 |
| Otsuka America Pharmaceutical, Inc. | 28 | $592 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $584 |
| MDD US Operations, LLC | 10 | $561 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $485 |
| Corium, LLC | 22 | $461 |
| Lundbeck LLC | 21 | $443 |
| Bausch Health US, LLC | 17 | $324 |
| Supernus Pharmaceuticals, Inc. | 14 | $280 |
| Teva Pharmaceuticals USA, Inc. | 10 | $200 |
| Axsome Therapeutics, Inc. | 7 | $183 |
| Eisai Inc. | 6 | $127 |
| Ironshore Pharmaceuticals Inc. | 6 | $127 |
| Alkermes, Inc. | 6 | $125 |
| Vertical Pharmaceuticals, LLC | 6 | $114 |
| Tempus AI, Inc | 5 | $111 |
| E.r. Squibb & Sons, L.L.C. | 4 | $108 |
| Idorsia Pharmaceuticals US Inc | 6 | $107 |
| Noven Therapeutics, LLC | 5 | $103 |
| Tris Pharma Inc | 5 | $103 |
| Almatica Pharma LLC | 5 | $93 |
| Neos Therapeutics, LP | 5 | $82 |
| Indivior Inc. | 4 | $76 |
| Jazz Pharmaceuticals Inc. | 3 | $69 |
| Neurocrine Biosciences, Inc. | 3 | $68 |
| Shire North American Group Inc | 3 | $48 |
| Adlon Therapeutics L.p. | 2 | $42 |
| Neuronetics, Inc. | 1 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Brainsway USA Inc | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$20,124
- SPRAVATO$2,354
- Lucemyra/Lofexidine$500
- CAPLYTA$122
- VYVANSE$112
How this compares
$30,729 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 14 | $26,962 |
| VraylarCariprazine Hcl | 16 | $20,860 |
| BelsomraSuvorexant | 12 | $5,186 |
| Lisdexamfetamine Dimesylate | 16 | $3,606 |
| Vilazodone Hcl | 25 | $3,042 |
| Aripiprazole | 26 | $2,804 |
| Eszopiclone | 44 | $2,750 |
| Lurasidone Hcl | 11 | $2,078 |
| Bupropion XlBupropion Hcl | 31 | $1,569 |
| Fluoxetine Hcl | 63 | $1,567 |
| Methylphenidate ErMethylphenidate Hcl | 36 | $1,427 |
| Oxcarbazepine | 25 | $1,420 |
| Duloxetine Hcl | 65 | $1,293 |
| Zaleplon | 25 | $850 |
| Olanzapine | 31 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $485 | $26,96214 claims |
| AbbVieVraylar | $21,686 | $20,86016 claims |
| Almatica Pharma LLCSertraline Hcl | $93 | $4722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Katy
- Vikram MehraKaty$1.2M
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.